Saturday 17 October 2026
Export ZTS’s income statement to Excel — free account
Zoetis Inc.
ZTS Healthcare Drug Manufacturers Specialty & Generic
Zoetis Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.5 billion, up 2.28% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 2.48%, free cash flow grew 17.4% and total debt rose 37.5%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years, revenue growth for ten; insiders bought in the last twelve months.
79.20
0.78
+0.99%
Follow ZTS
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
49.47% | 65.31% | 67.75% | 64.91% | |
Piotroski F-Score |
6 | 7 | 8 | 6 | |
| 17.82% | 17.98% | 18.27% | 17.84% | ||
ROIC |
19.89% | 20.99% | 20.22% | 19.60% | |
Return on Tangible Assets |
31.40% | 32.23% | 32.83% | 32.75% | |
Average Days of Receivables |
59.91 | 54.32 | 57.67 | 60.20 | |
Free Cash Flow per Share |
5.06 | 5.15 | 5.32 | 5.57 | |
Free Cash Flow |
2,240.00 | 2,283.00 | 2,247.00 | 2,327.00 | |
Capital Expenditures |
(676.00) | (621.00) | (543.00) | (513.00) | |
| Other line items | |||||
Cash ROIC |
15.39% | 15.31% | 15.80% | 16.77% | |
Accounts Receivable Turnover |
6.36 | 6.95 | 6.65 | 6.12 | |
Accounts Payable Turnover |
6.57 | 6.07 | 5.80 | 5.62 | |
Inventory Turnover |
1.09 | 1.12 | 1.09 | 1.08 | |
Average Days of Payables |
56.01 | 60.92 | 68.82 | 61.15 | |
Days of Inventory on Hand |
336.72 | 337.34 | 346.13 | 348.22 | |
Tax Rate |
(0.20) | (0.20) | (0.20) | (0.20) | |
Research and Development Expense of Revenue |
7.29% | 7.37% | 7.51% | 7.59% | |
Selling, General and Administrative Expense of Revenue |
25.48% | 25.12% | 25.10% | 24.88% | |
Share Based Compensation of Revenue |
0.85% | 0.88% | 0.95% | 1.00% | |
Interest Coverage |
16.30 | 16.14 | 15.54 | 14.86 | |
Operating CF/Net income |
1.11 | 1.09 | 1.04 | 1.08 | |
Depreciation/Fixed assets |
0.14 | 0.13 | 0.13 | 0.13 | |
Capex/Depreciation |
(1.38) | (1.28) | (1.11) | (1.06) | |
Revenue per Share |
21.20 | 21.35 | 22.58 | 22.81 | |
Operating CF per Share |
6.58 | 6.55 | 6.61 | 6.80 | |
Capex per Share |
(1.53) | (1.40) | (1.29) | (1.23) | |
Capex to Sales |
0.07 | 0.07 | 0.06 | 0.05 |
Columns are period end dates